PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
Abramson Cancer Center at Penn Medicine
Summary
This is a single center, prospective cross-sectional study of women who have completed therapy for primary breast cancer within 5 years of diagnosis and are at increased risk for relapse. Patients will undergo screening bone marrow aspirate to test for presence of disseminated tumor cells (DTCs) Patients who harbor DTCs will be offered the opportunity for enrollment into a clinical trial of therapy targeting DTCs to prevent recurrence (separate protocols).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Histologically-confirmed primary invasive breast cancer within 5 years of study entry * Qualifying risk status, at diagnosis utilizing receptor testing by ASCO/CAP guidelines, meeting at least one of the following: * Pathologically-confirmed invasive breast cancer in axillary lymph nodes, regardless of receptors * Primary tumor with triple negative subtype: estrogen receptor (ER) \< 10%, progesterone receptor (PR) \< 10% and negative Her2-overexpression by ASCO-CAP guidelines * Primary tumor that is ER+/Her2 negative/Lymph node negative with a Breast Cancer Recurr…
Interventions
- OtherResearch Blood Collection
Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)
Location
- Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania